Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation

血管生成 下调和上调 卵巢癌 癌症研究 血管内皮生长因子A 贝伐单抗 小RNA 生物 癌症 医学 血管内皮生长因子 内科学 化疗 基因 生物化学 血管内皮生长因子受体
作者
Taro Yagi,Kenjiro Sawada,Mayuko Miyamoto,Aasa Shimizu,Yukako Oi,Aska Toda,Koji Nakamura,Yasuto Kinose,Michiko Kodama,Kae Hashimoto,Tadashi Kimura
出处
期刊:Molecular Cancer Research [American Association for Cancer Research]
卷期号:21 (10): 1093-1106 被引量:11
标识
DOI:10.1158/1541-7786.mcr-23-0015
摘要

Abstract Although bevacizumab (BEV) plays a key role in ovarian cancer treatment, BEV resistance is often observed in clinical settings. This study aimed to identify the genes responsible for BEV resistance. C57BL/6 mice inoculated with ID-8 murine ovarian cancer cells were treated with anti-VEGFA antibody or IgG (control) twice weekly for 4 weeks. The mice were sacrificed, then, RNA was extracted from the disseminated tumors. qRT-PCR assays were performed to identify angiogenesis-related genes and miRNAs that were altered by anti-VEGFA treatment. SERPINE1/PAI-1 was found to be upregulated during BEV treatment. Therefore, we focused on miRNAs to elucidate the mechanism underlying the upregulation of PAI-1 during BEV treatment. Kaplan–Meier plotter analysis revealed that higher expression levels of SERPINE1/PAI-1 were associated with poor prognoses among BEV-treated patients, suggesting that SERPINE1/PAI may be involved in the acquisition of BEV resistance. miRNA microarray analysis followed by in silico and functional assays revealed that miR-143-3p targeted SERPINE1 and negatively regulated PAI-1 expression. The transfection of miR-143-3p suppressed PAI-1 secretion from ovarian cancer cells and inhibited in vitro angiogenesis in HUVECs. Next, miR-143-3p-overexpressing ES2 cells were intraperitoneally injected into BALB/c nude mice. ES2-miR-143-3p cells downregulated PAI-1 production, attenuated angiogenesis, and significantly inhibited intraperitoneal tumor growth following treatment with anti-VEGFA antibody. Continuous anti-VEGFA treatment downregulated miR-143-3p expression, which upregulated PAI-1 and activated an alternative angiogenic pathway in ovarian cancer. In conclusion, the substitution of this miRNA during BEV treatment may help overcome BEV resistance, and this may be used as a novel treatment strategy in clinical settings. Implications: Continuous administration of VEGFA antibody upregulates SERPINE1/PAI-1 expression via the downregulation of miR-143-3p, which contributes to acquiring bevacizumab resistance in ovarian cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FiFi完成签到 ,获得积分10
1秒前
2秒前
isabelle完成签到,获得积分10
2秒前
怪力花生完成签到,获得积分20
2秒前
3秒前
fsxadada123发布了新的文献求助10
4秒前
汉堡包的应助被幸运的成仁采纳,获得10
4秒前
科研小白发布了新的文献求助10
4秒前
4秒前
上岸发布了新的文献求助10
4秒前
云槿完成签到,获得积分10
5秒前
橙子发布了新的文献求助10
6秒前
xx发布了新的文献求助10
6秒前
6秒前
所所的应助被大气的fgyyhjj采纳,获得10
6秒前
xiaot完成签到,获得积分10
6秒前
徐长硕完成签到,获得积分20
6秒前
大模型的应助被故渊丶采纳,获得10
7秒前
7秒前
领导范儿的应助被欢喜若灵采纳,获得10
8秒前
大模型的应助被红雨灰衣采纳,获得10
8秒前
甜美山灵完成签到 ,获得积分10
9秒前
丘比特的应助被纯情的秋天采纳,获得10
9秒前
聪慧雪糕完成签到,获得积分20
9秒前
阳光的山水完成签到 ,获得积分10
9秒前
徐长硕发布了新的文献求助10
10秒前
ping发布了新的文献求助10
10秒前
LuXiaoyu的应助被oleskarabach采纳,获得10
10秒前
疯狂加载ing的应助被oleskarabach采纳,获得10
11秒前
牧百川发布了新的文献求助10
11秒前
12秒前
打打的应助被Felix0917采纳,获得10
12秒前
xiaot发布了新的文献求助10
12秒前
zzz发布了新的文献求助10
12秒前
13秒前
田様的应助被科研小白采纳,获得10
14秒前
tjzbw发布了新的文献求助10
15秒前
15秒前
研二就毕业完成签到,获得积分10
16秒前
晚霞跌落星河的应助被master采纳,获得30
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496